logo
episode-header-image
Mar 2024
7m 50s

Eli Lilly CEO Dave Ricks Talks Fighting ...

bloomberg
About this episode

Eli Lilly CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club of New York, the head of the pharma giant says that they are looking to create an oral tablet in addition to an injectable device and hopes to get them to the market quicker. 

See omnystudio.com/listener for privacy information.

Up next
Today
Dimensional Fund Advisors Chairman David Booth Talks Embracing Uncertainty
David Booth, Dimensional Fund Advisors founder and chairman, discusses the theme of his new book "Stay Calm: Learn to Embrace Uncertainty in Investing and Life," and his historic $300 Million gift to the University of Kansas. He speaks with hosts Caroline Hepker and Judy Lagrou.S ... Show More
17m 23s
Today
Partners Group CEO David Layton Talks Management Reshuffle
Partners Group Holding AG reshuffled its top management after a slump in first-half earnings and warned of a weaker outlook for performance fees. The company's outgoing CEO David Layton joins Bloomberg News' Dani Burger and Isabelle Lee on Tuesday to discuss the issues facing Par ... Show More
13m 22s
Yesterday
T. Rowe Price CEO Rob Sharps Talks Private Assets and AI Adoption
T. Rowe Price CEO Rob Sharps discusses how the company is adapting to the rise of passive investing. Speaking with Romaine Bostick, Sharps also says private assets are slowly moving into 401(k) plans and sees "tax-loss harvesting" as a growth area. He also discusses how the firm ... Show More
22m 16s
Recommended Episodes
Jan 2025
Dave Ricks
Eli Lilly is the world's most valuable drug company, known for its blockbuster anti-obesity drugs that's transforming America. In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see ... Show More
22m 38s
Feb 2025
Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
<p>Nicolai Tangen meets with David Ricks, CEO of&nbsp;Eli&nbsp;Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is&nbsp;Eli&nbsp;Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ... Show More
55m 40s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More
36m 59s
Apr 2025
ICYMI: Eli Lilly's New Weight Loss Pill
Shares in Eli Lilly surged on Friday  after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine. Shares of the drug’s originator Chugai ... Show More
7m 16s
Sep 2025
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
<p>(0:00) Introducing Eli Lilly CEO Dave Ricks</p> <p>(1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China</p> <p>(7:08) GLP-1 pricing and capital allocation after a breakout pharma product</p> <p>(12:56) Why Biotech VC has plummeted, " ... Show More
30m 40s
Aug 2024
Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24
<p>Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ... Show More
44m 46s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Aug 2025
Deep Dive: Novo Nordisk & Eli Lilly Stumble Into Next Phase of Ozempic Era
Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show More
11m 3s